TORONTO, Sept. 21 At the 12th Annual ScientificMeeting of the Heart Failure Society of America (HFSA) today Dr. Louis J.Ignarro, 1998 Nobel Prize winner in Physiology or Medicine for discovering thesignaling properties of nitric oxide, was the featured speaker in theExcellence in Basic Science Session. He was presented with the 2ndDistinguished Lecture Award in Basic Science immediately following hispresentation "Nitric Oxide as a unique signaling molecule in Physiology".This scientific session is the highlight basic science session at the HFSAAnnual Scientific Meeting.
Dr. Ignarro's presentation focused on the discovery of nitric oxide, agaseous neurotransmitter that naturally occurs in humans and found to havehealth benefits of great proportions. Nitric oxide works to increase thebody's blood flow, helping to keep blood vessels dilated and prevent bloodclotting, which in turn provides a defense mechanism against high bloodpressure, stroke and cardiac complication, such as heart attacks. It wasdiscovered while properties of nitro glycerin were being examined, leading tofindings that the body converts nitro glycerin into nitric oxide.
"We are honored to have Dr. Ignarro give the Distinguished Lecture inBasic Science at this year's HFSA Annual Scientific Meeting," said Dr. BarryGreenberg, HFSA President, and Professor of Medicine, and Director, AdvancedHeart Failure Treatment Program, University of California, San Diego.
Dr. Ignarro (Distinguished Professor of Pharmacology, UCLA) is theco-recipient of the 1998 Nobel Prize in Physiology or Medicine for discoveringthe signaling properties of nitric oxide, which is perhaps best known as themedical breakthrough that later led to the development of the drug Viagra. Dr.Ignarro has published numerous articles on his research, and is the founder ofthe Nitric Oxide Society and founder and editor-in-chief of "Nitric OxideBiology and Chemistry." In 1998 he received the Basic Research Prize of theAmerican Heart Association for his contributions in the field and advancementof cardiovascular science. Dr. Ignarro is an inductee of the National Academyof Sciences and the American Academy of Arts and Sciences.
For a complete list of annual meeting sessions or for details on attendingthe conference, call (617) 226-7192 or visit www.hfsa.org and click on AnnualScientific Meeting. There is no registration fee for accredited journalists.Interview areas will be available on-site in addition to a fully-staffed pressroom with phone and internet accessibility.
About Heart Failure
Heart failure is a progressive condition in which the heart muscle becomesweakened after it is injured from heart attack or high blood pressure andgradually loses its ability to pump enough blood to supply the body's needs.Many people are not aware they have heart failure because the symptoms areoften mistaken for signs of getting older. Heart failure affects from 4.6 to4.8 million individuals in the United States. Demographic and clinicalevidence strongly suggest the prevalence of heart failure will increasethroughout the next decade. Ten to 15 years ago heart failure was considered a"death sentence;" however, recent advances in treatment have shown that earlydiagnosis and proper care in early stages of the condition are key to slowing,stopping or in some cases reversing progression, improving quality of life,and extending life expectancy. For more information on heart failure, pleasevisit www.abouthf.org.
About the Heart Failure Society of America
The Heart Failure Society of America (HFSA) is a nonprofit educationalorganization, founded in 1994 as the first organized association of heartfailure experts. Today HFSA has over 1,700 members and provides a forum forall those interested in heart function, heart failure research and patientcare. The Society also serves as a resource for governmental agen